Senkyunolide A alleviates asthma by inhibiting TGF-β/Smad2/3 signaling pathway and NLRP3 inflammasome activation
Biochemical and Biophysical Research Communications · 2025
DOI: 10.1016/j.bbrc.2025.152809 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical and Biophysical Research Communications, 2025. Verfasst von Meng Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Center for Preventive Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China. Electronic address: qwert19981…. Hauptthemen laut MEDLINE: Asthma, Signal Transduction, NLR Family, Pyrin Domain-Containing 3 Protein, Inflammasomes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Asthma is a chronic disease characterized by airway remodeling, which results in a progressive decline in lung function. Senkyunolide A is one of the effective components of ligusticum chuanxiong Hort, it shows protective effects on many human diseases. However, the role of Senkyunolide A in asthma remains unclear. RESULTS: In our study, we established an asthma mouse model by ovalbumin (OVA) sensitization and challenge, and Senkyunolide A (20 mg/kg and 40 mg/kg) was given by intraperitoneal injection. For in vitro study, lung epithelial BEAS-2B cells were treated with TGF-β1 to induce epithelial mesenchymal transformation. Our study showed that Senkyunolide A (40 mg/kg) alleviated airway injury, inflammatory infiltration and airway remodeling induced by OVA in asthma mice. Meanwhile, Senkyunolide A (40 μM) recovered the high level of cell migration and profibrotic factors expression induced by TGF-β1. Mechanistically, Senkyunolide A abolished the effect of OVA or TGF-β1 on Smad2/3 phosphorylation at site Ser465/467/Ser423/425 in mice or BEAS-2B cells and inhibited the activation of NLRP3 inflammasome induced by OVA. CONCLUSIONS: In total, our study indicated that Senkyunolide A alleviated airway damage and airway remodeling in asthmatic mice and regulated the progress of asthma by inhibiting the TGF-β/Smad2/3 signaling pathway and NLRP3 activation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Preventive Medicine, First Affiliated Hospital, Heilongjiang University of Chinese Medicine, Harbin, China. Electronic address: qwert199810@126.com.
- Graduate School, Heilongjiang University of Chinese Medicine, Harbin, China.
Zitieren
APA
Zhang, M., Wang, C., Zhao, R., & Yuan, J. (2025). Senkyunolide A alleviates asthma by inhibiting TGF-β/Smad2/3 signaling pathway and NLRP3 inflammasome activation. Biochemical and Biophysical Research Communications. https://doi.org/10.1016/j.bbrc.2025.152809
Vancouver
Zhang M, Wang C, Zhao R, Yuan J. Senkyunolide A alleviates asthma by inhibiting TGF-β/Smad2/3 signaling pathway and NLRP3 inflammasome activation. Biochemical and Biophysical Research Communications. 2025. doi:10.1016/j.bbrc.2025.152809
BibTeX
@article{Zhang2025,
author = {Zhang, Meng and Wang, Congyao and Zhao, Ruiqi and Yuan, Jiabo},
title = {Senkyunolide A alleviates asthma by inhibiting TGF-β/Smad2/3 signaling pathway and NLRP3 inflammasome activation},
journal = {Biochemical and Biophysical Research Communications},
year = {2025},
doi = {10.1016/j.bbrc.2025.152809}
}
EUVIMED